Abiopharma

🔍 Lucidi Bruno (Executive)

Company: Atea Pharmaceuticals, Inc. (AVIR)

Report Date: 2026-06-18

Detailed Transactions and Holdings:

• Acquired 29,600 shares of Common Stock (Direct)
  Date: 2026-06-18 | Code: M | equity_swap_involved: false | shares_owned_after: 142,350.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 29,600 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-18 | Code: M | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F2, F2
• Acquired 26,700 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-18 | Code: A | equity_swap_involved: false | shares_owned_after: 26,700.00 | transaction_form_type: 4 | Footnotes: F1, F3, F3
• Acquired 37,700 shares of Stock Option (Right to Buy) at $4.36 per share (Derivative)
  Date: 2026-06-18 | Code: A | Expires: 2036-06-17 | equity_swap_involved: false | shares_owned_after: 37,700.00 | transaction_form_type: 4 | Footnotes: F4

Footnotes:

• F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
• F2: The RSUs vested in full on June 18, 2026.
• F3: The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after June 18, 2026 or (ii) June 18, 2027, in each case, subject to the Reporting Person's continued service through the applicable vesting date.
• F4: The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 18, 2026, such that the option shall be fully vested on June 18, 2027, subject to the Reporting Person's continued service through each such vesting date.